Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.

Официальное название

Investigating the Clinical Cure Rate and the Risk Reduction of Hepatocellular Carcinoma in Chronic HBV Infected Individuals With a Family History of Liver Cancer Using PegIFN α-2b Combined With NA Treatment in a Real-world Study.

Обзор

This is a retrospective prospective, open-label, multicenter clinical study aiming to recruit 400 individuals with a family history of liver cancer to explore the clinical cure rate and the effectiveness, feasibility, and safety of PEGylated interferon α-2b combined with nucleos(t)ide analogues in treating chronic HBV carriers with a family history of liver cancer for reducing the risk of liver cancer occurrence. Patients will enrolled into Group A (Peg-IFNα-2b combined with NA treatment group) or Group B (NA monotherapy group) based on their medication choices. Each group is expected to enroll 200 patients, with all patients followed up to 240 weeks. The dosage, frequency, and duration of treatment with Peg-IFN α-2b and NA will be prescribed by the researchers according to clinical practice and standard treatment protocols.

Вмешательства

• Препарат Peg-IFNα-2b combined with NA
  From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
• Препарат Nucleotide Analogues
  Starting from the first day of enrollment, take NA orally once a day.

Первичные конечные точки

• Clinical cure rate [Срок оценки: through study completion, an average of 24 weeks.]
• Liver cancer incidence rate [Срок оценки: through study completion, an average of 24 weeks.]

Вторичные конечные точки (7)

• The decrease in HBsAg compared to baseline. [Срок оценки: through study completion, an average of 24 weeks.]
• HBsAg seroconversion rate [Срок оценки: through study completion, an average of 24 weeks.]
• Changes of biomarkers after disease progression-related markers such as HBV DNA quantification compared to baseline. [Срок оценки: through study completion, an average of 24 weeks.]
• Incidence of abnormal and clinically relevant changes in vital signs [Срок оценки: through study completion, an average of 24 weeks.]
• Incidence of treatment-emergent adverse event (AE) [Срок оценки: through study completion, an average of 24 weeks.]
• Incidence of abnormal and clinically relevant changes in laboratory assessments [Срок оценки: through study completion, an average of 24 weeks.]
• Incidence of severe acute allergic reactions occurring during treatment. [Срок оценки: through study completion, an average of 24 weeks.]

Критерии участия

Критерии включения

• Age18-65 years (inclusive of 18 and 65), no restriction on gender;
• HBsAg positive history for at least 6 months;
• Family history of liver cancer \[including first-degree and second-degree relatives; first-degree relatives are parents, children, and siblings (same parents), while second-degree relatives are uncles, aunts, grandparents, and great-grandparents; a family history of liver cancer means that one or more first-degree or second-degree relatives have had liver cancer\];
• Planning to or already receiving treatment with Peginterferon alpha-2b in combination with nucleoside (acid) analogs, or receiving nucleoside (acid) analogs treatment alone;
• Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age);
• Willing to receive treatment and sign an informed consent form.

Критерии исключения

• Allergy to interferon;
• History of using telbivudine for antiviral treatment;
• ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal;
• Decompensated liver cirrhosis;
• Neutrophil count < 1.5 x 10\^9/L or platelet count < 80 x 10\^9/L;
• Presence of severe lesions in vital organs such as the cardiovascular, pulmonary, renal, brain, and fundus;
• Those with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid dysfunction (hyperthyroidism or hypothyroidism);
• Confirmed or suspected liver cancer or other malignant tumors;
• Post-organ transplant or preparing for organ transplantation;
• Currently using immunosuppressants;
• Pregnant or planning to become pregnant within 2 years;
• Alcohol or drug addicts;
• HIV co-infection;
• Other conditions deemed unsuitable for interferon use by the attending physician.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Случай-контроль

Центры проведения

Китай · 4 центра

• The Third Affiliated Hospital of Sun Yat-sen University — Гуанчжоу
• Chenzhou Second People's Hospital — Chenzhou
• First Affiliated Hospital of Nanhua University — Hengyang
• Hengyang Third People's Hospital — Hengyang

Идентификаторы

NCT: NCT06746701 · 202207428

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗